Atogepant
CAS 1374248-81-3 5 FDA-DMF suppliersSmall Molecule
Overview
Atogepant is a small molecule that acts as a calcitonin gene-related peptide (CGRP) receptor antagonist used in the prevention of migraine headaches. It is designed to provide oral preventive treatment for adult patients with episodic migraines.
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Atogepant expires 27 Feb 2043 and exclusivity 27 Sept 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
NeurologyMigraine
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.